Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Busulfan versus hydroxyurea in the treatment of polycythemia vera (PV) and essential thrombocythemia (ET)

Literature DB >> 9499248

Busulfan versus hydroxyurea in the treatment of polycythemia vera (PV) and essential thrombocythemia (ET)

I Brodsky.

Abstract

Entities: Chemical Disease

Mesh：

Substances：

Year: 1998 PMID： 9499248 DOI： 10.1097/00000421-199802000-00024

Source DB: PubMed Journal: Am J Clin Oncol ISSN： 0277-3732 Impact factor: 2.339

Keyword Cloud
Cited

× No keyword cloud information.

10 in total

1. Effect of busulfan on JAK2V617F allele burden.

Authors: Maria Luigia Randi; Claudia Santarossa; Edoardo Peroni; Elisabetta Cosi; Elena Duner; Irene Bertozzi; Fabrizio Fabris
Journal: Haematologica Date: 2014-01-03 Impact factor: 9.941

2. JAK2V617F allele burden is reduced by busulfan therapy: a new observation using an old drug.

Authors: Emil T Kuriakose; Stefani Gjoni; Y Lynn Wang; Ruth Baumann; Amy V Jones; Nicholas C P Cross; Richard T Silver
Journal: Haematologica Date: 2013-11 Impact factor: 9.941

3. Decrease in JAK2 V617F allele burden is not a prerequisite to clinical response in patients with polycythemia vera.

Authors: Emil Kuriakose; Katherine Vandris; Y Lynn Wang; William Chow; Amy V Jones; Paul Christos; Nicholas C P Cross; Richard T Silver
Journal: Haematologica Date: 2011-11-18 Impact factor: 9.941

Review 4. Polycythaemia vera and essential thrombocythaemia in the elderly.

Authors: P J van Genderen; M M Troost
Journal: Drugs Aging Date: 2000-08 Impact factor: 3.923

5. Dehydroalanine analog of glutathione: an electrophilic busulfan metabolite that binds to human glutathione S-transferase A1-1.

Authors: Islam R Younis; Meenal Elliott; Cody J Peer; Arthur J L Cooper; John T Pinto; Gregory W Konat; Michal Kraszpulski; William P Petros; Patrick S Callery
Journal: J Pharmacol Exp Ther Date: 2008-09-12 Impact factor: 4.030

10. Long-term and low-dose of busulfan is a safe and effective second-line treatment in elderly patients with essential thrombocythemia resistant or intolerant to hydroxyurea.

Authors: Rossella Renso; Andrea Aroldi; Pietro Pioltelli; Carlo Gambacorti-Passerini; Elena Maria Elli
Journal: Blood Cancer J Date: 2018-06-11 Impact factor: 11.037

10 in total

Busulfan versus hydroxyurea in the treatment of polycythemia vera (PV) and essential thrombocythemia (ET)

1. Effect of busulfan on JAK2V617F allele burden.

2. JAK2V617F allele burden is reduced by busulfan therapy: a new observation using an old drug.

3. Decrease in JAK2 V617F allele burden is not a prerequisite to clinical response in patients with polycythemia vera.

Review 4. Polycythaemia vera and essential thrombocythaemia in the elderly.

5. Dehydroalanine analog of glutathione: an electrophilic busulfan metabolite that binds to human glutathione S-transferase A1-1.

6. Busulfan for the treatment of myeloproliferative neoplasms: the Mayo Clinic experience.

Review 7. Essential thrombocythemia treatment algorithm 2018.

Review 8. Polycythemia vera treatment algorithm 2018.

Review 9. Polycythemia vera: historical oversights, diagnostic details, and therapeutic views.

10. Long-term and low-dose of busulfan is a safe and effective second-line treatment in elderly patients with essential thrombocythemia resistant or intolerant to hydroxyurea.